key: cord-0328873-jvpv7dhj
authors: Garst, Emma; Lee, Hwayoung; Das, Tandrila; Bhattacharya, Shibani; Percher, Avital; Wiewiora, Rafal; Witte, Isaac P.; Li, Yumeng; Goger, Michael; Peng, Tao; Im, Wonpil; Hang, Howard C.
title: Site-specific lipidation enhances IFITM3 membrane interactions and antiviral activity
date: 2020-09-11
journal: bioRxiv
DOI: 10.1101/2020.09.11.293324
sha: 099b538b5487ba4fad631c159e25a950346e6aa3
doc_id: 328873
cord_uid: jvpv7dhj

Interferon-induced transmembrane proteins (IFITMs) are S-palmitoylated proteins in vertebrates that restrict a diverse range of viruses. S-palmitoylated IFITM3 in particular directly engages incoming virus particles, prevents their cytoplasmic entry, and accelerates their lysosomal clearance by host cells. However, the precise molecular mechanisms of action for IFITM-mediated viral restriction are still unclear. To investigate how site-specific S-palmitoylation controls IFITM3 antiviral activity, here we employed computational, chemical, and biophysical approaches to demonstrate that site-specific lipidation of IFITM3 at highly conserved cysteine 72 modulates its conformation and interaction with lipid membranes leading to enhanced antiviral activity of IFITM3 in mammalian cells. Collectively, our results demonstrate that site-specific S-palmitoylation of IFITM3 directly alters its biophysical properties and activity in cells to prevent virus infection.

of-function allele has been identified in the IFITM3 gene 5' untranslated region (SNP 6 rs34481144), and is associated with lower IFITM3 mRNA expression and a decrease in 7 airway resident CD8 + T cells during viral infection (Allen et al., 2017). Significantly, a 8 recent small human cohort study showed that the rs12252 SNP was also associated 9

with a higher incidence of severe COVID-19 (Y. Zhang et al., 2020b) . Previously, human coronavirus OC43 (Zhao et al., 2014; . Early studies on the role of the 13

IFITMs in SARS-CoV-2 infection have been inconclusive. In initial screening and 14 overexpression studies, IFITM2 and IFITM3 were found to inhibit SARS-CoV- 2 15 pseudotyped virus (X. Zhang et al., 2020a) , and IFITMs were shown to inhibit SARS-16

CoV-2 spike protein mediated cell-cell fusion (Buchrieser et al., 2020) . However, 17

conflicting studies have observed that SARS-CoV-2 pseudotyped virus infection (Zheng 18 et to coronaviruses, a mechanistic understanding of the activity of IFITMs will be key in 30 delineating their roles in coronavirus infections. 31 32 Cellular studies of IFITMs have begun to reveal key features of their antiviral activity. 33 Immunofluorescence ( revealed that IFITM3 directly engages incoming virus-containing vesicles and 39

accelerated their trafficking to lysosomes for destruction. Lipid mixing assays showed 40 that IFITM3 does not prevent viral hemifusion with host membranes (Desai et al., 2014) , 41 suggesting that IFITMs may inhibit virus pore formation. Although the antiviral 42 mechanism of IFITM3 is still unclear, two non-exclusive models for the restriction of viral 43 particles have emerged (Figure 1 ). IFITM3 could actively accelerate the degradation of 44 viral particles by manipulation of cellular trafficking pathways, as observed by live cell 45 imaging studies (Spence et al., 2019) . Alternatively, IFITM3 may physically restrict the 46 virus infection by altering the biophysical properties of host membranes. This is 1 supported by recent studies indicating that IFITM3 can increase the order and rigidity of 2 endosomal membranes as well as induce negative curvature that could potentially 3 stabilize a hemifused state while inhibiting viral pore formation (Guo et al., 2020; Rahman et al., 2020). Both of these mechanisms may account for the observed antiviral 24 25 IFITMs were originally proposed to be dual-pass transmembrane proteins (Brass et al., single-pass transmembrane protein with an amphipathic region from residue Trp60 to 31

Arg85 containing two a-helices (Figure 1 -figure supplement 1 

mutagenesis, a number of point mutations within these regions at post-translational 1 modification (PTM) sites or within putative oligomerization motifs were found to disrupt 2 the antiviral activity of IFITM3 (John et al., 2013) . Moreover, mutations within the first 3 amphipathic helix (Val59-Met68) that altered IFITM3 hydrophilicity abrogated the 4 antiviral activity, indicating that the amphipathic nature of this helix is required for its 5 antiviral function (Chesarino et al., 2017) . Furthermore, amphipathic helix 1 can alter the 6 biophysical characteristics of the phospholipid bilayer by inducing negative curvature, 7

increasing lipid order, and increasing membrane stiffness (Guo et al., 2020) . These 8 studies confirm that the conserved amphipathic region of IFITM3 is necessary for the 9

restriction of viral particles in the endocytic pathway, possibly through the direct 10 manipulation of the local membrane environment. 11 12 IFITM3 activity is regulated by a number of PTMs such as S-palmitoylation (Cys71, 13

Cys72, and Cys105), ubiquitination (Lys24, Lys83, Lys88, and Lys104), phosphorylation 14 (Tyr20), and methylation (Lys88) (Chesarino et al., 2014a) . The interplay between these 15

PTMs has been implicated in the localization, activity, and turnover of IFITM3. 16 Methylation 2017). These studies demonstrate that site-specific and regulated S-palmitoylation of 31

IFITMs is particularly crucial for their antiviral activity, but these studies were primarily 32 from loss-of-function phenotypes and did not demonstrate if site-specific lipidation 33

confers gain-of-function.

S-Palmitoylation is a reversible PTM in eukaryotes. S-Palmitoylation targets peripheral 36 membrane proteins to specific cellular membranes (Rocks et al., 2010) and can act as a 37

sorting mechanism in cells without specific receptor-ligand pairing (Rocks et al., 2005 2010), the functional analysis of site-specific S-palmitoylation, which may be sub-46 stoichiometric in cells, is still challenging. To investigate how S-palmitoylation enhances 1 the antiviral activity of IFITMs, we employed in silico as well as chemical strategies to 2 evaluate site-specifically lipidated IFITM3 structure in vitro and antiviral activity in 3 mammalian cells. Our molecular dynamics simulation studies, the reconstitution of 4 chemically lipidated IFITM3 in vitro (Figure 1 -figure supplement 1) , and solution-5

state NMR spectroscopy analysis suggest that site-specific S-palmitoylation of IFITM3 6

at Cys72 induces conformational changes in the amphipathic helices and N-terminal 7

domain, and anchor these cytoplasmic domains to cellular membranes. To complement 8

these in silico and in vitro structural studies, we used genetic code expansion and 9

bioorthogonal ligation methods with tetrazine-lipid analogs that our laboratories recently 10 developed (Li Y et al in review, Supplemental File) for site-specific lipidation of 11 IFITM3 in mammalian cells (Figure 1 -figure supplement 1) . These studies showed 12 that site-specific chemical lipidation enhanced IFITM3 antiviral activity in mammalian 13 cells, providing additional support for our modeling and structural studies in vitro. 14 Collectively, our studies highlight the importance of site-specific lipidation methods to 15

investigate gain-of-function phenotypes for S-palmitoylation and underscores the 16 significance of this PTM for the antiviral activity and biochemical properties of IFITMs. 17 18 19 RESULTS 20

Molecular dynamics simulation of S-palmitoylated IFITM3 and chemically 21 lipidated variants. To understand how site-specific S-palmitoylation controls the 22

interaction of IFITM3 with the membrane bilayer, we used molecular dynamics to 23 simulate IFITM3 in a variety of lipidation states. For these studies, human IFITM3 was 24 modeled in a 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) bilayer without 25 palmitoylation (apo), with a palmitoyl group at Cys72 (Cys72-Palm), or with a stable 26 maleimide-palmitoylation mimic (Cys72-mPalm) (Figure 2A) . We found that S-27 palmitoylation at Cys72 altered the positioning of the amphipathic region of IFITM3, 28

particularly within the first amphipathic helix (AH1, Leu62-Phe67) (Figure 2A) . To 29 quantify and compare the effects of palmitoylation, we calculated the distance of the 30 center of mass of each helix from the membrane center (at Z = 0) throughout the 1-µs 31 simulation ( Figure 2B ). When unmodified, AH1 remained water exposed with an 32 average distance of 26.5 Å away from the membrane center. Conversely, Cys72 33 palmitoylation led to increased membrane proximity in AH1, reducing its average 34 distance from the membrane center to 16.1 Å near the membrane head group. The 35

Cys72-mPalm modification also brought AH1 into close proximity with the membrane 36 bilayer, showing an average distance of 9.1 Å (below the head group). Although similar 37

in effect, the closer association of the mPalm-modified construct suggests that the 38 maleimide head group of the palmitoyl mimic may either be able to insert AH1 better 39 into the membrane bilayer or form stronger interactions with the phospholipids 40

compared to the thioester of natural S-palmitoylation. Interestingly, AH2 in all models 41

showed similar orientation and positioning regardless of Cys72 palmitoylation despite its 42

proximity to the lipid modification. Thus, S-palmitoylation may lead to localized and 43 specific changes in protein structure and dynamics. 44 45 In addition to AH1 membrane association, we also measured the helical tilt of the a-1 helical segments (with respect to the membrane normal) throughout the simulations. 2

These data show that when IFITM3 is not palmitoylated, AH1 is a flexible segment that 3

can sample many orientations ( Figure 2C) . Additionally, during the simulation, the AH1 4 region frequently contacted water molecules, while only occasionally contacting the 5 phospholipid head groups, as might be expected of a soluble peptide rather than one 6

with amphipathic tendencies (Figure 2D ). In contrast, when IFITM3 is modified at 7

Cys72 either with a naturally occurring palmitoyl group or maleimide-palmitate, the AH1 8 is restricted to the surface of the model membrane, sampling a tight range of helical tilts 9

around 90° from the membrane normal and interacting with water, the phospholipid 10 head groups, and the lipid tails in relatively equal parts (Figure 2C, D) . In the case of 11 loop 2 (residue 86 to 97), the apo model interacts much more frequently with the 12 phospholipid head groups compared to the lipidated models (Cys72-Palm and Cys72-13 mPalm), indicating the effect of lipidation on IFITM3 dynamics can be seen on both the 14 N-and C-terminal side of the modification up to 20 residues away ( Figure 2D) . No 15 notable difference was observed in the interactions between the transmembrane 16 domain and its surrounding environments throughout all systems. Together, these data 17

indicate that lipidation at Cys72 may be required for the proper folding and anchoring of 18 IFITM3 AH1 despite its relative distance from AH1, and more significantly its location 19

past a short disordered region. Moreover, this molecular simulation indicates that 20

maleimide-palmitate can function as a reasonable mimic of S-palmitoylation for our 21 structural and biochemical studies. 

Generation of recombinant site-specifically lipidated IFITM3. To further understand 22

how site-specific lipidation regulates IFITM3, we optimized the expression and 23

purification of recombinant human His6-tagged IFITM3 from E. coli and employed 24 maleimide-palmitate (mPalm) for site-specific lipidation of key Cys residues ( Figure  25 3A). Maleimide-palmitate was used due to its cysteine specific reactivity and potential 26

for full length protein labeling in detergents. In order to optimize the maleimide coupling 27

reaction, we tested a number of conditions including time, temperature, maleimide- HNCACO) were used to assign the backbone resonances. Sequential assignments 28

were facilitated by 15 N specific labeling of specific residues (Ala, Leu, Val, Ile, and Phe) 29

to alleviate resonance overlap and allow the assignment of residues proximal to the site 30 of lipidation ( Figure 4B and Figure 4 -figure supplement 1) . In total, we were able to 31

assign 70% and 75% of the His6-Cys72-mPalm and His6-apo IFITM3 protein backbones 32 respectively (Figure 4 -figure supplement 2 and Figure 4 -figure supplement 3) . 33 The backbone chemical shifts were analyzed in TALOS+ ( Bax, 2009) to determine the secondary structure of His6-IFITM3, which was highly a-1

helical in the C-terminal domain (residue Ser61 to Gly133) ( Figure 4C ). In the N-2

terminal region, both His6-apo and His6-Cys72-mPalm IFITM3 had a high percentage of 3 dynamic residues (26.7% and 35%, respectively). The random coil index (RCI) 4

predicted order parameter S 2 confirmed that the N-terminal domain of both protein 5

constructs is highly dynamic (Figure 4 -figure supplement 4) 

In the ordered C-terminal domain, our secondary structure analysis revealed three a-9

helices similar to previously published structural work on His6-IFITM3 (Ling et al., 2016). 10

However, we found a number of notable differences from this published work in both the 11 amphipathic region and the transmembrane domain. Two helices were observed in the 12 amphipathic region for both the His6-apo-IFITM3 and His6-Cys72-mPalm-IFITM3 13

constructs: AH1 from Ser61 to Phe67 and AH2 from Cys71 to Lys83 ( Figure 4C ). In our 14

analysis, AH2 was three residues longer than the published structure (which stretches 15

from Ile76 to Arg85) and now contained the functional lipidation site, Cys72. Moreover, 16

our data suggest a loop region from Lys104 to Asn107 followed by a 23-amino acid 17

helix between Ile108 and Ala131 ( Figure 4C) , differing from the previously described 18 33-amino acid transmembrane domain (Ala98-Ala131) (Ling et al., 2016) . 19 20

When comparing the secondary structure of our chemically lipidated and non-lipidated 21 constructs, we found subtle changes in the amphipathic region while the global 22

secondary structure remained the same. Lipidation at Cys72 caused a small decrease 23

in the a-helical confidence directly C-terminal to the site of modification (Phe75 to 24

Ala77) ( Figure 4C) . Furthermore, lipidation at Cys72 increased the helical propensity of 25 residues Ala100 to Lys104, possibly indicating the stabilization of a third amphipathic 26 helix in the region. These changes are indicative of a localized effect on the structure of 27 IFITM3; however, lipidation does not destabilize the existing secondary structure of 28 IFITM3 overall, consistent with our molecular dynamics simulations (Figure 2 ). 29 30 We also used chemical shift perturbation (CSP) analysis to quantify the effect of lipid 31 modification on the structure of His6-IFITM3 ( Figure 4D ). This analysis utilizes the 32 change in chemical shift of the amide backbone peaks to measure the magnitude of 33 effect for some change to the protein or environment, in this case the addition of a lipid 34

analogue at Cys72. This analysis revealed that maleimide-palmitate modification at 35

Cys72 had a significant effect on the local protein structure with an average perturbation 36 of 0.049 ppm in the conserved amphipathic region from residue Trp60 to Arg85 (three 37

times that of the standard deviation threshold, s0). For residue Leu73, directly adjacent 38

to the site of lipidation, the CSP value reached 0.175 ppm (ten times the threshold 39 value). Surprisingly, lipidation at Cys72 also seemed to have an effect on the 40 disordered, soluble N-terminal domain, where 5 residues (Val5, Gln6, Phe9, Ser10, and 41

Arg49) had a CSP value twice that of the standard deviation threshold. Although 42

unexpected, this could be due in part to a change in how the disordered N-terminal 43

region interacts with the DPC micelle when the amphipathic region of His6-IFITM3 is 44

anchored to the membrane via a lipid analogue. This analysis indicates that although 45 the most distinct change in the structure of IFITM3 is in the region proximal to the site of 46 modification, lipidation at Cys72 can cause distal changes in the IFITM3 backbone. 1 These results demonstrate that Cys72-lipidation can significantly affect the backbone 2 conformation of IFITM3 and provides a potential structural link between the lipid 3 modification and increased antiviral activity of Cys72-lipidated IFITM3. 

(quantified in Figure 4D ). Asterisks note residues without backbone assignment. C) The secondary 12 structures of His6-apo and His6-Cys72-mPalm IFITM3 were predicted using TALOS+ based on chemical the liposomes (Figure 5A ). 32 33 To focus on the activity of the disordered and amphipathic regions of IFITM3, we 34 designed a truncated construct (Met1-Leu106) that lacked the transmembrane domain 35

and fused it to a cleavable His6-SUMO domain for improved expression. After purifying 36

His6-SUMO-apo IFITM3 and His6-SUMO-Cys72 IFITM3 from the crude lysate with a Ni-37

NTA column, the SUMO domain was cleaved by ULP1 and IFITM3 was coupled to 38 mPalm as previously described. The 1-106 IFITM3 constructs were then separated from 39

the His6-SUMO domain by size exclusion. Successful purification and mPalm coupling 40

was confirmed by MALDI analysis (Figure 5 -figure supplement 2) . After purification, 41

these truncated IFITM3 constructs were mixed with preformed 100 nm liposomes and 42 dialyzed overnight to remove any detergent. Full length His6-apo IFITM3 and His6-43

SUMO were used as positive and negative controls, respectively. For the flotation 44 assay, these protein-containing liposomes were added to a Histodenz density gradient 45

and centrifuged at 150,000 x g for 3 hours. The sample was then fractionated and 46

analyzed using SDS-PAGE to determine whether the protein was associated with the 47 liposome. Since full length IFITM3 is an integral membrane protein, it fully associated 48

with liposomes and was only found in the top fraction ( Figure 5B ). His6-SUMO, which 49 has no membrane binding properties, was found in the bottom three fractions ( Figure  1  5B) . For the truncated IFITM3 constructs, liposome binding was correlated with 2 lipidation at Cys72 (Figure 5B) . Indeed, when we quantified the protein content across 3 the density gradient, on average only 35% of apo 1-106 IFITM3 was present in the 4 liposome-associated fraction, whereas Cys72-mPalm 1-106 IFITM3 was largely found in 5 this first fraction (on average 68% of the total liposome protein content) (Figure 5C ). 6 These results show that lipidation at Cys72 increases the affinity of the amphipathic 7 region of IFITM3 with the phospholipid bilayer, indicating that lipidation may be required 8

to anchor the extended amphipathic region to the membrane, which is consistent with 9

our molecular dynamics simulations (Figure 2 ). Tukey's test (*p < 0.05, ***p < 0.0005).

The following figure supplement is available for figure 5: with the tetrazine-lipid mimic Tz-6 ( Figure 6 -figure supplement 2) . We also 30 evaluated the ligation efficiency with other tetrazine-lipid analogues of shorter aliphatic 31 chain length (Tz-1) and higher hydrophilicity (Tz-PEG) (Figure 6 -figure supplement  32  3a) . HA-IFITM3-Cys72TAG showed efficient chemical labeling independent of the 33 nature of the tetrazine derivatives (Figure 6 -figure supplement 3b,c) . These results 34

show that the UAAs are successfully incorporated at specific sites in IFITM3 via genetic 35

code expansion and can be modified with tetrazine derivatives for site-specific chemical 36 lipidation of IFITM3 in live cells. 37 38 We next evaluated the virus susceptibility of HEK293T cells expressing lipidated 39 IFITM3-Cys72TAG. Cells were infected by H1N1 influenza virus (IAV) for 6 hours, and 40 viral infection was measured by staining of viral nucleoprotein (NP) and HA-IFITM3 by 41 flow cytometry. IFITM3 with AlkK at Cys72 cannot undergo tetrazine ligation and 42

showed no change in antiviral activity on addition of Tz-6 ( Figure 6F) . However, cells 43 expressing IFITM3 constructs containing 2'-aTCOK and exo-BCNK showed decreased 44 viral susceptibility upon treatment with Tz-6 ( Figure 6F) , restoring approximately 35% of 45 the antiviral activity of wild type IFITM3 when compared with a Cys72 to Ala loss-of-46 function mutant (Figure 6G) . Immunofluorescence imaging of the cells expressing 1 IFITM3 with exo-BCNK at Cys72 show endolysosomal localization similar to 2 endogenous IFITM3 in HeLa cells (Figure 6 -figure supplement 4) . Moreover, 3

labeling with tetrazine-lipid mimic Tz-6 showed no evident difference in subcellular 4 localization (Figure 6 -figure supplement 4) , suggesting the changes induced by site-5 specific lipidation may be on local membrane interactions rather than drastic changes in 6 cellular distribution. Notably, this live cell chemical lipidation approach provides the first 7 evidence for gain-of-function by site-specific lipidation of IFITM3 in mammalian cells and 8

underscores the significance of Cys72 S-palmitoylation in IFITM3 antiviral activity. Data were analyzed by unpaired Student's t-test (**p < 0.005).

The following figure supplements are available for figure 6: IFITMs are key immune effectors conserved across vertebrates that protect against a 20 broad range of viral pathogens. S-palmitoylation was previously found to be essential 21

for the antiviral activity of IFITM3, but the direct effects of palmitoylation on its structure 22

and cellular activity have not been explored due to a lack of accessible chemical tools. 23

Since S-palmitoylation is required for IFITM3 antiviral activity, a better understanding of 24

site-specific lipidation is central to delineating its mechanism of action. By developing 25

new methods for the generation of lipidated IFITM3 both in vitro and in vivo, we have 26 been able to directly probe the biophysical and cellular consequences of IFITM3 S-27

palmitoylation.

The study of S-fatty acylated proteins in vitro and in cells has been challenging due to 30

the hydrophobicity of the modification as well as its reversibility and substoichiometric 31 levels in cells (Linder & Deschenes, 2007; Resh, 2006) . To address these challenges, 32

site-selective bioconjugation methods, protein semi-synthesis, and genetic code 33 expansion have been employed to attach lipid analogs to proteins (Hang & Linder, 34 2011). Using maleimide-palmitate, we have been able to generate lipid-modified 35 recombinant IFITM3 for a range of biochemical and biophysical studies. Molecular 36 dynamics simulations of S-palmitoylated IFITM3 and maleimide-palmitate modified 37

IFITM3 were conducted to determine if maleimide palmitate is an appropriate mimic for 38 a native S-palmitoyl modification. Both the natural palmitoyl thioester and the synthetic 39 mimic yielded similar structural changes in our computational models, indicating that 40 maleimide-palmitate is a reasonable substitute for S-palmitoylation. Surprisingly, the 41 molecular dynamics simulations also revealed a significant change in the structure of 42 the amphipathic region of IFITM3 when lipidated, with the stabilization of the functionally 43 significant AH1 region. Indeed, when Cys72-maleimide palmitate modified IFITM3 was 44 compared with unmodified IFITM3 using NMR, we found structural changes both locally 45 and in the disordered N-terminal region. Furthermore, a flotation assay revealed the 46 disordered and amphipathic regions of Cys72-mPalm IFITM3 had increased association 47

with the membrane bilayer. We note that maleimide-palmitate modified IFITM3 does not 48

contain the native thioester linkage, which could be addressed through biophysical 49 For cellular studies, protein semi-synthesis (Rocks et al., 2005 ; 2010) of site-specifically 4

lipidated Ras isoforms has been instrumental in elucidating the reversible features of S-5 palmitoylated peripheral membrane proteins in mammalian cells. However, IFITMs are 6

S-palmitoylated type IV membrane proteins that may not insert into cellular membranes 7

properly and are therefore not ideal for microinjection studies. More recently, genetic 8 code expansion has been used to site-specifically functionalize proteins with lipid 9 mimics (Li Y et al in review, Supplemental File) . Here, we have leveraged the method 10 developed by Li Y et al. to chemically lipidate cellular IFITM3, expanding the scope of 11 the technique to integral membrane proteins. This has allowed us to conduct the first 12 antiviral gain-of-function assay of lipidated IFITM3 in mammalian cells, confirming the 13 importance of site-specific S-fatty acylation in the regulation of IFITM3 antiviral activity. 14 15

Together, our results provide the first direct evidence that lipidation can change the 16 biophysical properties of IFITM3. As the disruption of AH1 is known to attenuate the be important for the prevention of future disease outbreaks. In summary, our findings 37

illuminate important links between the protein structure, membrane association, and 38 antiviral activity of IFITM3, and underscore the significance of integrated in silico, 39 chemical, biophysical, and cellular studies of S-fatty acylation. force-based switching method (Steinbach & Brooks, 1994) was used for the van der 29

Waals interactions under 10 to 12 angstrom cut-off range. To reduce the uncertainty of 30

sequence-based structure, 1.5 µs of preliminary simulation was performed and the 31 coordinate information from that of simulation was used for the later simulation. Among 32 1 µs of production runs, the last 500 ns trajectories were used for analysis, and each 33 system has 3 replicas to obtain better sampling.

Maleimide palmitate synthesis 36 A round bottom flask was charged with 0.68 g of triphenylphosphine (2.57 mmol, 0.9 37 eq.) and 17.5 ml of tetrahydrofuran. The flask was placed under argon and cooled to -78 38 °C. 1.18 ml of the 40% solution of diethyl azodicarboxylate in toluene (2.57 mmol, 0.9 39 eq.) were added over a period of 3 minutes. The resulting mixture was stirred for 5 40 minutes, after which a solution of 0.7 g of hexadecan-1-ol (2.87 mmol, 1 eq.) in a 41 minimal amount of THF (prepared in an argon purged vial) was added over a period of 1 42 minute. The resulting solution was stirred for 5 minutes. The flask's septum was then 43 removed under the protection of an argon curtain and 0.125 g of neopentyl alcohol (1. 43 44 mmol, 0.5 eq.) and 0.25 g of maleimide (2.57 mmol, 0.9 eq.) were added as solids. The 45

flask was closed again under argon and the reaction mixture was stirred for 5 minutes, 46 after which the cooling bath was removed and the reaction stirred at room temperature 1 for 16 hours, then at 40 °C for 2 hours. After full conversion was indicated by TLC, the 2 solvent was evaporated in vacuo. The resulting solid was purified by silica flash 3 chromatography (loading and elution in dichloromethane His6-apo IFITM3 sample, 70 out of 115 predicted dihedral angles were found to be 18 "good" by TALOS+. Of the other residues, 19 residues were predicted to be dynamic 19

(84% of which were in the disordered N-terminal region from residue Met1 to Val59) and 20 26 residues were found to be ambiguous. Out of those residues, 8 were in the 21 structured C-terminal domain (Trp60 to Gly133) while 18 were in the disordered N-22

terminal region (Met1 to Val59). In the His6-Cys72-mPalm IFITM3 sample, 68 out of 106 23

predicted dihedral angles were found to be "good" by TALOS+, while 25 residues were 24 predicted to be dynamic (21 residues in the disordered N-terminal region, 4 residues in 25 the structured C-terminal region). 13 residues were found to be ambiguous, with 5 in the 26 structured C-terminal domain and 8 in the disordered N-terminal region. For the 27 chemical shift perturbation analysis, the chemical shift differences were calculated using 28 a weighted average of the Euclidean distance moved:

The standard deviation of the change in chemical shift across the protein was calculated 33

and used as a threshold value (s0) to identify residues with significant changes in 34 chemical shift (Williamson, 2013 Abcam. Alexa-Fluor 647 Antibody Labeling Kit (A20186) was ordered from Life 23

Technologies. Anti-HA antibody conjugated to Alexa-Fluor 594 was purchased from Life 24

Technologies. Anti-HA HRP-conjugated antibody was ordered from Roche.

Plasmid transfection 27 pCMV-Mm-PylRS-WT plasmid was kindly provided by Professor Peng R. Chen at 28

Peking University (Zhang et al., 2011) . pCMV-FLAG-Mm-PylRS-AF (Y306A and Y384F 29 double mutant of wild-type PylRS) were generated in the lab by site-directed 30 mutagenesis of pCMV-Mm-PylRS-WT and introducing an in-frame N-terminal FLAG 31

tag. Human IFITM3 cDNA was purchased from Open Biosystems and PCR cloned into 32

pCMV-HA vector (Clontech). All mutants of IFITM3 were generated by using 33

QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies, #200523).

Lipofectamine 3000 from Thermo Scientific was used for transfection of HEK293T cells.

Chemical lipidation of IFITM3 37

HEK293T cells were seeded on 6-well plates and cultured overnight. The next day cells 38

were co-transfected with the plasmid encoding aminoacyl-tRNA synthetase/tRNA pair 39

Mm-PylRS-AF (Y306A, Y384F)/Pyl-tRNA (0.5 µg) and HA-IFITM3-Cys72TAG (0.5 µg) 40 using 3 µL Lipofectamine 3000 in complete cell growth media containing UAAs (100 41 μM) for 16 h. Then cells were treated with tetrazine-lipid (20 μM) for 2 h. Cells were 42 lysed with 4% SDS lysis buffer (4% SDS, 150 mM NaCl, 50 mM triethanolamine pH 7.4, 43

Roche protease inhibitor, benzonase). Protein concentrations were determined by the 44 BCA assay (Pierce). Protein concentration of cell lysate was normalized to 1.6 μg/ml. 45 46 1 45 μl of the cell lysate was treated with 5 μl of CuAAC reactant solution (0.5 μl of 10 mM 2 azido-rhodamine (final concentration 100 μM), 1 μl of 50 mM freshly prepared 3

CuSO4·5H2O in H2O (final concentration 1 mM, Sigma), 1 μl of 50 mM freshly prepared 4 TCEP (final concentration 1 mM) and 2.5 μl of 10 mM Tris[(1-benzyl-1H-1,2,3-triazol-4-5 yl)methyl]amine (TBTA) (final concentration 500 μM)) was added. The samples were 6 rocked at room temperature for 1 h. 7 8

In-gel fluorescence profiling and western blot 9

Protein pellet was precipitated by using a mixture of methanol-chloroform-H2O (4:1.5:3, 10 relative to sample volume). After mixing by inversion several times, samples were 11 centrifuged at 20,000x g for 5 min at 4°C. Two separate phases were observed with a 12

protein pellet between the two. After carefully removing the aqueous (top) layer, 1 mL of 13

prechilled methanol was added and centrifuged. After another wash with methanol, the 14 protein pellet was dried using speed-vacuum for 10 min. The pellet was resuspended in 15

1X Laemmli sample buffer (20 μl) and was heated for 10 min at 95 °C and separated by 16 gel electrophoresis. In-gel fluorescence scanning was performed using a Bio-Rad 17

ChemiDoc MP Imaging System. Gels were transferred to nitrocellulose membranes 18

using BioRad Trans-Blot Semi-Dry Cell (20 V, 40 min), which were blocked with PBST 19

(0.05% Tween-20 in PBS) containing 5% nonfat milk for 1 h at room temperature. The 20

membranes were then incubated with anti-HA HRP conjugate (3F10, Roche, 1:2000 21 dilution) overnight at 4 °C. After overnight incubation, membranes were washed with 22

PBST three times and developed using Bio-Rad Clarity Western ECL substrate and 23

imaged with a Bio-Rad ChemiDoc MP Imager. Quantification of band intensities in 24 fluorescence gels and Western blotting were performed with Image Lab (Bio-Rad). Data 25 from three biological replicates were quantified and averaged for plotting.

Influenza A virus infection assay 28 For the infection assay, HEK293T cells were transfected and treated as described 29

above to express chemically lipidated IFITM3. Then the cells were infected program through the NIH Chemistry-Biology Training Grant T32 GM115327. A. Percher 4 was supported by an NSF Graduate Research Fellowship. We thank P.D.R Olinares  5 and B.T. Chait for technical assistance and discussion of MALDI analysis. We thank M. 6

Griffin, J. Yount, and T. Walz for helpful discussion and input into this manuscript. The 7 data collected at NYSBC was made possible by a grant from ORIP/NIH facility 8 improvement grant CO6RR015495. The 900 MHz NMR spectrometers were purchased 9

with funds from NIH grant P41GM066354 and the New York State Assembly. T. Peng 10 acknowledges support from National Natural Science Foundation of China (21778010) 11 and Shenzhen Science and Technology Innovation Committee 12

(JCYJ20170412150832022). This work was supported by NSF MCB-1810695 (to W. 13 Im) and NIH-NIGMS R01GM087544 grant (to H.C. Hang). 14 15 16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46 

IFITM proteins inhibit placental syncytiotrophoblast formation and promote 1 fetal demise

Syncytia formation by SARS-CoV-2 infected cells

IFITM3 requires an amphipathic helix for antiviral 8 activity

Regulation of the trafficking 10 and antiviral activity of IFITM3 by post-translational modifications

Phosphorylation of the Antiviral Protein Interferon-inducible Transmembrane Protein 14 3 (IFITM3) Dually Regulates Its Endocytosis and Ubiquitination

Expanding and Reprogramming the Genetic Code of Cells and 18 Animals

Isothermal-isobaric molecular dynamics 21 simulations with Monte Carlo volume sampling

Natural mutations in IFITM3 modulate post-translational regulation and toggle 25 antiviral specificity

IFITM3 Restricts Influenza A Virus Entry by Blocking the Formation of Fusion Pores 29 following Virus-Endosome Hemifusion

OpenMM 7: Rapid development of high performance algorithms for 33 molecular dynamics

The Pfam protein families database in 2019

A smooth particle mesh Ewald method

IFITM3 restricts the morbidity and mortality associated with influenza

Transcriptional and posttranscriptional regulation of interferon-induced gene 46 expression in human cells

Efficient Algorithms for Langevin and DPD Dynamics

Transmembrane Protein 3 Blocks Fusion of Diverse Enveloped 6 Viruses by Locally Altering Mechanical Properties of

Exploring Protein Lipidation with Chemical Biology

The chemical toolbox for monitoring protein fatty 11 acylation and prenylation

Chemical Synthesis of the 14 Highly Hydrophobic Antiviral Membrane Associated Protein IFITM3 and Modified 15 Variants

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is 19 Blocked by a Clinically Proven Protease Inhibitor

Chloroquine does not inhibit infection of human lung cells with 23 SARS-CoV-2

Chemical Synthesis of Native S-Palmitoylated Membrane Proteins through

Assisted Ser/Thr Ligation

Distinct Patterns of IFITM-Mediated Restriction of Filoviruses, 30 SARS Coronavirus, and Influenza A Virus

An Implicit Membrane Generalized Born 33 Theory for the Study of Structure

Generalized born model with a simple 36 smoothing function

Respiratory DC Use IFITM3 to Avoid Direct Viral Infection and Safeguard 40 Virus-Specific CD8+ T Cell Priming

CHARMM-GUI 43 PDB Manipulator for Advanced Modeling and Simulations of Proteins Containing 44 Nonstandard Residues

CHARMM-GUI: A web-based graphical 1 user interface for CHARMM

CHARMM-GUI Membrane Builder for

Mixed Bilayers and Its Application to Yeast Membranes

The CD225 domain of IFITM3 is required for both IFITM protein association 8 and inhibition of influenza A virus and dengue virus replication

Comparison of simple potential functions for simulating liquid water. The 12

IFITM3 protects the heart during influenza virus infection

Update of the CHARMM all-atom additive force field for 19 lipids: validation on six lipid types

Palmitoylated calnexin is a key component of the 23 ribosome&ndash

Cellular incorporation of unnatural amino acids and 26 bioorthogonal labeling of proteins

Palmitoylation regulates raft affinity for the majority of integral raft proteins

Palmitoylation: policing protein stability and 33 traffic

Combined 36 approaches of EPR and NMR illustrate only one transmembrane helix in the human 37 IFITM3

Adding New Chemistries to the Genetic Code

Lack of Truncated IFITM3 Transcripts in Cells Homozygous for the 43 rs12252-C Variant That is Associated With Severe Influenza Infection

Synthesis and in 46 vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride 1 lipase inhibitors

The palmitoyltransferase ZDHHC20 enhances interferon-5 induced transmembrane protein 3 (IFITM3) palmitoylation and antiviral activity. The 6

Site-Specific Bioorthogonal Labeling for Fluorescence 9 Imaging of Intracellular Proteins in Living Cells

Mass-tag labeling reveals site-specific and endogenous levels of protein S-fatty 13 acylation

IFITMs Restrict the 16 Replication of Multiple Pathogenic Viruses

IFITM proteins promote SARS-CoV-2 infection in human lung cells

Chemistry in living systems

Homology-guided identification of a conserved motif linking the antiviral 25 functions of IFITM3 to its oligomeric state

Evaluation of IFITM3 rs12252 Association With Severe Pediatric 28 Influenza Infection

Trafficking and signaling by fatty-acylated and prenylated proteins

Reconstitution of membrane proteins into liposomes

The Palmitoylation Machinery Is a Spatially Organizing System for 37 Peripheral Membrane Proteins

An acylation cycle regulates localization and activity of palmitoylated Ras 41 isoforms

Numerical Integration of the 44 Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of 45 n-Alkanes

The IFITMs Inhibit Zika Virus Replication

A diverse range of gene products are effectors of the type I 5 interferon antiviral response

trans-Cyclooctene -a stable, voracious dienophile 8 for bioorthogonal labeling

TALOS+: a hybrid method for 11 predicting protein backbone torsion angles from NMR chemical shifts

Opposing activities of IFITM proteins in SARS-CoV-2 infection

IFITM3 directly engages and shuttles incoming virus particles to lysosomes

New spherical-cutoff methods for long-range 20 forces in macromolecular simulation

Interferon-induced transmembrane protein 3 blocks fusion of sensitive 24 but not resistant viruses by partitioning into virus-carrying endosomes

Constitutively Expressed IFITM3 Protein in Human Endothelial Cells Poses an Early 28 Infection Block to Human Influenza Viruses

Expanding room for tetrazine ligations in the in 31 vivo chemistry toolbox

CHARMM All-Atom Additive Force Field for Sphingomyelin: Elucidation of 35 Hydrogen Bonding and of Positive Curvature

Enhanced survival 38 of lung tissue-resident memory CD8+ T cells during infection with influenza virus 39 due to selective expression of IFITM3

The Molecular Signature of Tissue Resident Memory CD8 T Cells 43 Isolated from the Brain

Membrane Topology Model for Human Interferon Inducible Transmembrane Protein

Using chemical shift perturbation to characterise ligand 3 binding

CHARMM-GUI Membrane Buildertoward realistic biological membrane 7 simulations

Intrinsic Immunity Shapes Viral Resistance of Stem Cells

Site-13 Specific Photo-Crosslinking Proteomics Reveal Regulation of IFITM3 Trafficking and 14 Turnover by VCP/p97 ATPase

Palmitoylation supports assembly and function of integrin-tetraspanin complexes

IFITM proteins drive type 2 T helper cell differentiation and exacerbate allergic 22 airway inflammation

S-palmitoylation and 25 ubiquitination differentially regulate interferon-induced transmembrane protein 3 26 (IFITM3)-mediated resistance to influenza virus

Palmitoylome profiling reveals S-30 palmitoylation&ndash;dependent antiviral activity of IFITM3

Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking 34 membrane fusion

Interferon-induced transmembrane proteins inhibit cell fusion mediated 37 by trophoblast syncytins

Structure-Function Analysis

Distinct Requirements for Tumor Cell Behaviors 41 Mediated by α3β1 versusα6β4 Integrin

Viral and host factors 44 related to the clinical outcome of COVID-19

Interferon-Induced

Transmembrane Protein 3 Genetic Variant rs12252-C Associated With Disease 2 Severity in Coronavirus Disease

Interferon-induced transmembrane protein-3 genetic variant rs12252-C is 6 associated with severe influenza in Chinese individuals

Interferon induction of IFITM proteins promotes infection by human coronavirus 10 OC43

Identification of 13 Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on 14 Entry of Human Coronaviruses

Bat SARS-Like 17 WIV1 coronavirus uses the ACE2 of multiple animal species as receptor and evades 18 IFITM3 restriction viaTMPRSS2 activation of membrane fusion. Emerging Microbes 19 & Infections